An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Prospective Study Evaluating the Quality of Life in Dialysis Patients With End Stage Renal Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01105494

Enrollment

6000

Registered

2010-04-16

Start date

2008-12-31

Completion date

2012-06-30

Last updated

2012-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Brief summary

This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta \[Neorecormon\] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.

Interventions

DRUGepoetin beta [NeoRecormon]

As prescribed by physician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients \>/=18 years of age * Dialysis patients with chronic renal anemia * Written informed consent

Exclusion criteria

* Red blood cell transfusion in the previous 2 months * Severe neuropsychological disorder * Diabetic patients with serious complications This trial is being conducted in Morocco.

Design outcomes

Primary

Measure	Time frame
Quality of life assessment: Kidney Disease Quality of Life Questionnaire	Throughout study: 6 months

Secondary

Measure	Time frame
Evaluation of factors (demographic and social characteristics, dialysis method) influencing the quality of life	Throughout study: 6 months

Countries

Morocco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026